title: Effect of short-term GH and testosterone administration on body composition and glucose homoeostasis in men receiving chronic glucocorticoid therapy.
abstract: OBJECTIVE
  Long-term pharmacological glucocorticoid (GC) therapy leads to skeletal muscle atrophy and weakness. The objective of this study was to investigate whether short-term treatment with GH and testosterone (T) can increase lean mass without major impairment of glucose homoeostasis in patients on GC therapy.
  
  
  METHODS
  This was a prospective, open-label, randomised, crossover study. Twelve men (age 74±6 years) on chronic GC treatment participated. The effects of 2 weeks' treatment with GH, testosterone and the combination of both on lean body mass (LBM), appendicular skeletal muscle mass (ASMM), extracellular water (ECW), body cell mass (BCM) and plasma glucose concentrations were investigated.
  
  
  RESULTS
  LBM increased significantly after GH (Δ1.7±1.4 kg; P=0.007) and GH+testosterone (Δ2.4±1.1 kg; P=0.003), but not testosterone alone. ASMM increased after all three treatment periods; by 1.0±0.8 kg after GH (P=0.005), 1.7±0.4 kg after GH+testosterone (P=0.002) and 0.8±1.0 kg after testosterone (P=0.018). The increase in ASMM was larger with combined treatment than either GH or testosterone alone (P<0.05). ECW increased significantly after GH+testosterone by 1.5±2.6 l (P=0.038) but not after GH or testosterone alone. BCM increased slightly after single and combined treatments, but the changes were not significant. Fasting glucose increased significantly after GH (Δ0.4±0.4 mmol/l, P=0.006) while both fasting (Δ0.2±0.3 mmol/l, P=0.045) and post glucose-load (Δ1.8±2.3 mmol/l, P=0.023) plasma glucose concentrations increased after GH+testosterone.
  
  
  CONCLUSIONS
  GH and testosterone induce favourable and additive body compositional changes in men on chronic, low-dose GC treatment. In the doses used, combination therapy increases fasting and postprandial glucose concentration.
authors.affiliation: Department of Endocrinology, Sahlgrenska University Hospital and Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gröna Stråket 8, SE-413 45 Göteborg, Sweden. oskar.ragnarsson@medic.gu.se
authors.forename: Oskar
authors.initials: O
authors.lastname: Ragnarsson
authors.forename: Morton G
authors.initials: MG
authors.lastname: Burt
authors.forename: Ken K Y
authors.initials: KK
authors.lastname: Ho
authors.forename: Gudmundur
authors.initials: G
authors.lastname: Johannsson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001284:Atrophy / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D001786:Blood Glucose / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects*; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000473:pathology; D011111:Polymyalgia Rheumatica / Q000188:drug therapy / Q000473:pathology; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D013739:Testosterone / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D005938:Glucocorticoids; D007328:Insulin; D019382:Human Growth Hormone; D013739:Testosterone; D011239:Prednisolone